Literature DB >> 16440059

Innate immunity mediated by TLR9 modulates pathogenicity in an animal model of multiple sclerosis.

Marco Prinz1, Folker Garbe, Hauke Schmidt, Alexander Mildner, Ilona Gutcher, Karina Wolter, Matthias Piesche, Roland Schroers, Elisabeth Weiss, Carsten J Kirschning, Christian D P Rochford, Wolfgang Brück, Burkhard Becher.   

Abstract

Inflammatory diseases of the CNS, such as MS and its animal model EAE, are characterized by infiltration of activated lymphocytes and phagocytes into the CNS. Within the CNS, activation of resident cells initiates an inflammatory cascade, leading to tissue destruction, demyelination, and neurologic deficit. TLRs recognize microbes and are pivotal mediators of innate immunity. Within the CNS, augmented TLR expression during EAE is observed, even in the absence of any apparent microbial involvement. To determine the functional relevance of this phenomenon during sterile autoimmunity, we studied the role of different TLRs as well as their common signaling adaptor MyD88 in the development of EAE. We found that MyD88 mice were completely EAE resistant. Surprisingly, this protection is partly due to engagement of the CpG receptor TLR9. Restricting the MyD88 or TLR9 mutation to host radio-resistant cells, including the cells within the CNS, revealed that engagement of radio-resistant cells modulated the disease course and histopathological changes. Our data clearly demonstrate that both TLR9 and MyD88 are essential modulators of the autoimmune process during the effector phase of disease and suggest that endogenous "danger signals" modulate the disease pathogenesis.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16440059      PMCID: PMC1350999          DOI: 10.1172/JCI26078

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  43 in total

1.  A Toll-like receptor recognizes bacterial DNA.

Authors:  H Hemmi; O Takeuchi; T Kawai; T Kaisho; S Sato; H Sanjo; M Matsumoto; K Hoshino; H Wagner; K Takeda; S Akira
Journal:  Nature       Date:  2000-12-07       Impact factor: 49.962

Review 2.  Prognosis of multiple sclerosis: environmental factors.

Authors:  I Casetta; E Granieri
Journal:  Neurol Sci       Date:  2000       Impact factor: 3.307

3.  Toll-like receptors control activation of adaptive immune responses.

Authors:  M Schnare; G M Barton; A C Holt; K Takeda; S Akira; R Medzhitov
Journal:  Nat Immunol       Date:  2001-10       Impact factor: 25.606

4.  Leptospiral lipopolysaccharide activates cells through a TLR2-dependent mechanism.

Authors:  C Werts; R I Tapping; J C Mathison; T H Chuang; V Kravchenko; I Saint Girons; D A Haake; P J Godowski; F Hayashi; A Ozinsky; D M Underhill; C J Kirschning; H Wagner; A Aderem; P S Tobias; R J Ulevitch
Journal:  Nat Immunol       Date:  2001-04       Impact factor: 25.606

5.  The innate immune response to bacterial flagellin is mediated by Toll-like receptor 5.

Authors:  F Hayashi; K D Smith; A Ozinsky; T R Hawn; E C Yi; D R Goodlett; J K Eng; S Akira; D M Underhill; A Aderem
Journal:  Nature       Date:  2001-04-26       Impact factor: 49.962

6.  Cellular responses to bacterial cell wall components are mediated through MyD88-dependent signaling cascades.

Authors:  O Takeuchi; K Takeda; K Hoshino; O Adachi; T Ogawa; S Akira
Journal:  Int Immunol       Date:  2000-01       Impact factor: 4.823

7.  Endosomal translocation of vertebrate DNA activates dendritic cells via TLR9-dependent and -independent pathways.

Authors:  Kei Yasuda; Philipp Yu; Carsten J Kirschning; Beatrix Schlatter; Frank Schmitz; Antje Heit; Stefan Bauer; Hubertus Hochrein; Hermann Wagner
Journal:  J Immunol       Date:  2005-05-15       Impact factor: 5.422

Review 8.  Genetic models for CNS inflammation.

Authors:  T Owens; H Wekerle; J Antel
Journal:  Nat Med       Date:  2001-02       Impact factor: 53.440

9.  Immune cell activation by bacterial CpG-DNA through myeloid differentiation marker 88 and tumor necrosis factor receptor-associated factor (TRAF)6.

Authors:  H Häcker; R M Vabulas; O Takeuchi; K Hoshino; S Akira; H Wagner
Journal:  J Exp Med       Date:  2000-08-21       Impact factor: 14.307

10.  The clinical course of experimental autoimmune encephalomyelitis and inflammation is controlled by the expression of CD40 within the central nervous system.

Authors:  B Becher; B G Durell; A V Miga; W F Hickey; R J Noelle
Journal:  J Exp Med       Date:  2001-04-16       Impact factor: 14.307

View more
  124 in total

1.  VBP15, a novel anti-inflammatory, is effective at reducing the severity of murine experimental autoimmune encephalomyelitis.

Authors:  Blythe C Dillingham; Susan M Knoblach; Gina M Many; Brennan T Harmon; Amanda M Mullen; Christopher R Heier; Luca Bello; John M McCall; Eric P Hoffman; Edward M Connor; Kanneboyina Nagaraju; Erica K M Reeves; Jesse M Damsker
Journal:  Cell Mol Neurobiol       Date:  2014-11-13       Impact factor: 5.046

Review 2.  The potential of mesenchymal stromal cells as a novel cellular therapy for multiple sclerosis.

Authors:  Jeffery J Auletta; Amelia M Bartholomew; Richard T Maziarz; Robert J Deans; Robert H Miller; Hillard M Lazarus; Jeffrey A Cohen
Journal:  Immunotherapy       Date:  2012-05       Impact factor: 4.196

Review 3.  The role of the gut microbiome in systemic inflammatory disease.

Authors:  Jose C Clemente; Julia Manasson; Jose U Scher
Journal:  BMJ       Date:  2018-01-08

4.  Phagocytes containing a disease-promoting Toll-like receptor/Nod ligand are present in the brain during demyelinating disease in primates.

Authors:  Lizette Visser; Marie-José Melief; Debby van Riel; Marjan van Meurs; Ella A Sick; Seiichi Inamura; Jeffrey J Bajramovic; Sandra Amor; Rogier Q Hintzen; Leonie A Boven; Bert A 't Hart; Jon D Laman
Journal:  Am J Pathol       Date:  2006-11       Impact factor: 4.307

5.  Designing inorganic nanomaterials for vaccines and immunotherapies.

Authors:  Krystina L Hess; Igor L Medintz; Christopher M Jewell
Journal:  Nano Today       Date:  2019-05-29       Impact factor: 20.722

6.  Design of Polyelectrolyte Multilayers to Promote Immunological Tolerance.

Authors:  Lisa H Tostanoski; Yu-Chieh Chiu; James I Andorko; Ming Guo; Xiangbin Zeng; Peipei Zhang; Walter Royal; Christopher M Jewell
Journal:  ACS Nano       Date:  2016-09-07       Impact factor: 15.881

7.  The type I IFN induction pathway constrains Th17-mediated autoimmune inflammation in mice.

Authors:  Beichu Guo; Elmer Y Chang; Genhong Cheng
Journal:  J Clin Invest       Date:  2008-05       Impact factor: 14.808

8.  Antiinflammatory properties of a plant-derived nonsteroidal, dissociated glucocorticoid receptor modulator in experimental autoimmune encephalomyelitis.

Authors:  Geert van Loo; Mozes Sze; Nadia Bougarne; Jelle Praet; Conor Mc Guire; Andrea Ullrich; Guy Haegeman; Marco Prinz; Rudi Beyaert; Karolien De Bosscher
Journal:  Mol Endocrinol       Date:  2009-12-04

9.  Polyplexes assembled from self-peptides and regulatory nucleic acids blunt toll-like receptor signaling to combat autoimmunity.

Authors:  Krystina L Hess; James I Andorko; Lisa H Tostanoski; Christopher M Jewell
Journal:  Biomaterials       Date:  2016-11-30       Impact factor: 12.479

10.  Regulatory role of TLR ligands on the activation of autoreactive T cells by retinal astrocytes.

Authors:  Guomin Jiang; Yan Ke; Deming Sun; Yali Wang; Henry J Kaplan; Hui Shao
Journal:  Invest Ophthalmol Vis Sci       Date:  2009-05-14       Impact factor: 4.799

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.